ES2721001T3 - Derivado de isoindolina, y composiciones y métodos para tratar una enfermedad neurodegenerativa - Google Patents
Derivado de isoindolina, y composiciones y métodos para tratar una enfermedad neurodegenerativa Download PDFInfo
- Publication number
- ES2721001T3 ES2721001T3 ES15743281T ES15743281T ES2721001T3 ES 2721001 T3 ES2721001 T3 ES 2721001T3 ES 15743281 T ES15743281 T ES 15743281T ES 15743281 T ES15743281 T ES 15743281T ES 2721001 T3 ES2721001 T3 ES 2721001T3
- Authority
- ES
- Spain
- Prior art keywords
- treat
- compositions
- methods
- neurodegenerative disease
- isoindoline derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/58—[b]- or [c]-condensed
- C07D209/62—Naphtho [c] pyrroles; Hydrogenated naphtho [c] pyrroles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461934528P | 2014-01-31 | 2014-01-31 | |
| PCT/US2015/013754 WO2015116923A1 (en) | 2014-01-31 | 2015-01-30 | Isoindoline compositions and methods for treating neurodegenerative disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2721001T3 true ES2721001T3 (es) | 2019-07-26 |
Family
ID=53757753
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES15743281T Active ES2721001T3 (es) | 2014-01-31 | 2015-01-30 | Derivado de isoindolina, y composiciones y métodos para tratar una enfermedad neurodegenerativa |
| ES19154222T Active ES2915833T3 (es) | 2014-01-31 | 2015-01-30 | Composiciones de isoindolina y métodos para tratar una enfermedad neurodegenerativa y una degeneración macular |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES19154222T Active ES2915833T3 (es) | 2014-01-31 | 2015-01-30 | Composiciones de isoindolina y métodos para tratar una enfermedad neurodegenerativa y una degeneración macular |
Country Status (15)
| Country | Link |
|---|---|
| US (5) | US9796672B2 (enExample) |
| EP (3) | EP3498692B1 (enExample) |
| JP (1) | JP6517827B2 (enExample) |
| KR (1) | KR102331422B1 (enExample) |
| CN (1) | CN106163516B (enExample) |
| AU (1) | AU2015210852B2 (enExample) |
| BR (1) | BR112016017808B1 (enExample) |
| CA (1) | CA2938212C (enExample) |
| DK (2) | DK3099296T3 (enExample) |
| ES (2) | ES2721001T3 (enExample) |
| IL (1) | IL247003B (enExample) |
| MX (1) | MX368755B (enExample) |
| NZ (1) | NZ722599A (enExample) |
| RU (1) | RU2692258C2 (enExample) |
| WO (1) | WO2015116923A1 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA037918B1 (ru) | 2011-12-21 | 2021-06-07 | Новира Терапьютикс, Инк. | Противовирусные агенты против гепатита в |
| HK1208465A1 (en) | 2012-08-28 | 2016-03-04 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
| DK2961732T3 (en) | 2013-02-28 | 2017-07-10 | Janssen Sciences Ireland Uc | SULFAMOYLARYLAMIDS AND USE THEREOF AS MEDICINES TO TREAT HEPATITIS B |
| WO2014161888A1 (en) | 2013-04-03 | 2014-10-09 | Janssen R&D Ireland | N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
| JO3603B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
| ES2774749T3 (es) | 2013-07-25 | 2020-07-22 | Janssen Sciences Ireland Unlimited Co | Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis B |
| KR102290189B1 (ko) | 2013-10-23 | 2021-08-17 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 카르복스아미드 유도체 및 ｂ형 간염 치료용 의약으로서의 이의 용도 |
| US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| DK3099296T3 (en) * | 2014-01-31 | 2019-04-15 | Cognition Therapeutics Inc | ISO-INDOLINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE |
| KR20160128305A (ko) | 2014-02-05 | 2016-11-07 | 노비라 테라퓨틱스, 인코포레이티드 | Hbv 감염의 치료를 위한 병용 요법 |
| DK3102572T3 (en) | 2014-02-06 | 2019-02-04 | Janssen Sciences Ireland Uc | SULFAMOYLPYRROLAMIDE DERIVATIVES AND THEIR USE AS MEDICINES TO TREAT HEPATITIS B |
| WO2016149581A1 (en) | 2015-03-19 | 2016-09-22 | Novira Therapeutics, Inc. | Azocane and azonane derivatives and methods of treating hepatitis b infections |
| US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
| HK1259410A1 (zh) | 2015-09-29 | 2019-11-29 | 诺维拉治疗公司 | 乙型肝炎抗病毒剂的晶体形式 |
| US11046670B2 (en) | 2015-10-19 | 2021-06-29 | Board Of Regents, The University Of Texas System | Piperazinyl norbenzomorphan compounds and methods for using the same |
| EP3442524A2 (en) | 2016-04-15 | 2019-02-20 | Novira Therapeutics Inc. | Combinations and methods comprising a capsid assembly inhibitor |
| EP3448520A4 (en) * | 2016-04-29 | 2020-07-29 | Board Of Regents, The University Of Texas System | SIGMA RECEIVER BINDERS |
| CN107162944B (zh) * | 2017-04-27 | 2019-02-26 | 湖南化工研究院有限公司 | 2,3-二甲基苯甲硫醚的制备方法 |
| IL270251B2 (en) * | 2017-05-15 | 2025-01-01 | Cognition Therapeutics Inc | 1-Phenyl-1,1-dimethyl-2-(piperidinyl/pyrrolidinyl/piperazinyl)ethane derivatives and pharmaceutical preparations containing them |
| EP3704092A4 (en) * | 2017-11-01 | 2021-08-25 | Cognition Therapeutics, Inc. | ISOINDOLINE COMPOSITIONS AND METHODS OF TREATMENT OF NEURODEGENERATIVE DISEASE |
| EA202092171A1 (ru) | 2018-03-14 | 2020-12-01 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Схема дозирования модулятора сборки капсида |
| JP6567153B1 (ja) * | 2018-09-28 | 2019-08-28 | 学校法人東北工業大学 | 対象化合物の特性の予測を行うための方法、コンピュータシステム、プログラム |
| CA3116348A1 (en) * | 2018-10-31 | 2020-05-07 | Polycore Therapeutics Llc | Method for synthesizing d3 dopamine receptor agonists |
| MA55020A (fr) | 2019-02-22 | 2021-12-29 | Janssen Sciences Ireland Unlimited Co | Dérivés d'amide utiles dans le traitement d'une infection par le virus de l'hépatite b ou de maladies induites par le virus de l'hépatite b |
| CN109734638A (zh) * | 2019-03-08 | 2019-05-10 | 新昌县大船畈生物科技有限公司 | 一种食用香精香料的制备方法 |
| CN109734639B (zh) * | 2019-03-08 | 2020-10-09 | 漯河市卫龙生物技术有限公司 | 一种食用香精香料的制备方法 |
| BR112021021454A2 (pt) | 2019-05-06 | 2021-12-21 | Janssen Sciences Ireland Unlimited Co | Derivados de amida úteis no tratamento da infecção por hbv ou doenças induzidas por hbv |
| US12352719B2 (en) | 2019-09-20 | 2025-07-08 | KYCERA AVX Components Corporation | Somatic cell-based electrical biosensor |
| CN112694427B (zh) * | 2019-10-23 | 2022-11-18 | 江西天宇化工有限公司 | 一种制备2,3-二甲基苯甲硫醚的方法 |
| EP4103604A4 (en) * | 2020-02-13 | 2024-03-27 | Cognition Therapeutics, Inc. | Method of decreasing amyloid beta monomer levels in patients with cognitive decline |
| JP2023526515A (ja) | 2020-05-20 | 2023-06-21 | ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイ | リソソーム蓄積症をヒスタチンペプチドで処置するための方法 |
| EP4259129A4 (en) * | 2020-12-11 | 2024-11-27 | Cognition Therapeutics, Inc. | COMPOSITIONS FOR THE TREATMENT OF DRY AGE-RELATED MACULAR DEGENERATION (AMD) |
| IL306063A (en) * | 2021-03-19 | 2023-11-01 | Cognition Therapeutics Inc | Preparations and methods for the treatment of neurological diseases |
| US20250177351A1 (en) * | 2022-07-18 | 2025-06-05 | Cognition Therapeutics, Inc. | Isoindoline compositions and methods for treating neurodegenerative disease |
| WO2024130030A1 (en) * | 2022-12-14 | 2024-06-20 | Fred Hutchinson Cancer Center | Method for treating neurological diseases through glial pruning regulation |
| WO2024196799A2 (en) * | 2023-03-17 | 2024-09-26 | Cognition Therapeutics, Inc. | Isoindoline compositions and methods for treating neurodegenerative disease |
| CN117945980A (zh) | 2024-01-24 | 2024-04-30 | 上海健康医学院 | 一种异吲哚硫亚胺类化合物及其制备和作为sigma-2受体抑制剂的应用 |
Family Cites Families (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA732136B (en) | 1972-04-12 | 1974-03-27 | Lilly Co Eli | Dopamine derivatives |
| DE2753278A1 (de) | 1977-11-30 | 1979-05-31 | Basf Ag | Aralkylpiperidinone |
| US4321386A (en) | 1981-01-28 | 1982-03-23 | Mead Johnson & Company | Quaternary piperidinium halides |
| DE3222152A1 (de) | 1982-06-12 | 1983-12-15 | Bayer Ag, 5090 Leverkusen | Substituierte maleinsaeureimide, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel |
| EP0117647B1 (en) | 1983-01-31 | 1988-08-17 | Eli Lilly And Company | Improvements in or relating to phenethanolamines |
| JPS62283922A (ja) | 1986-05-30 | 1987-12-09 | Tsumura Juntendo Inc | 血小板凝集抑制剤 |
| US4697024A (en) | 1986-11-24 | 1987-09-29 | Merrell Dow Pharmaceuticals Inc. | Medroxalol intermediates |
| US4958029A (en) * | 1987-01-13 | 1990-09-18 | Banyu Pharmaceutical Co., Ltd. | Process for the production of isoindoline derivatives, novel intermediates and process for their production |
| JPH01180822A (ja) | 1988-01-12 | 1989-07-18 | Dainippon Pharmaceut Co Ltd | 抗遅延型アレルギー剤 |
| JPH01305085A (ja) | 1988-05-31 | 1989-12-08 | Yamanouchi Pharmaceut Co Ltd | ピリジルチアゾリジンカルボン酸アミド誘導体 |
| JPH02215789A (ja) | 1989-02-15 | 1990-08-28 | Yamanouchi Pharmaceut Co Ltd | チアゾロ［３，４―ａ］ピラジン誘導体 |
| CA2071897A1 (en) | 1989-12-28 | 1991-06-29 | Richard A. Glennon | Sigma receptor ligands and the use thereof |
| DE4000610A1 (de) | 1990-01-11 | 1991-07-18 | Knoll Ag | Verfahren zur herstellung von optisch aktiven 3-amino-1-arylbutanen und 3-benzylamino-1-arylbutanen |
| JP2818958B2 (ja) | 1990-02-23 | 1998-10-30 | 塩野義製薬株式会社 | ４―（４―アルコキシフェニル）―２―ブチルアミン誘導体およびその製造法 |
| JPH045266A (ja) | 1990-04-24 | 1992-01-09 | Toyo Pharma- Kk | ドパミン誘導体の製造方法 |
| DE4142366A1 (de) | 1991-07-15 | 1993-06-24 | Thomae Gmbh Dr K | Phenylalkylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| US6011068A (en) | 1991-08-23 | 2000-01-04 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
| DK0724561T3 (da) | 1991-08-23 | 2004-06-28 | Nps Pharma Inc | Calciumreceptoraktive arylalkylaminer |
| US6610493B1 (en) | 1993-06-17 | 2003-08-26 | Brigham And Women's Hospital | Screening compounds for the ability to alter the production of amyloid-β peptide |
| CA2115900A1 (en) | 1993-02-22 | 1994-08-23 | Gerald W. Becker | Pharmaceutical screens and antibodies |
| JPH06321781A (ja) | 1993-05-13 | 1994-11-22 | Yamanouchi Pharmaceut Co Ltd | 血小板活性化因子拮抗剤 |
| CN1147459C (zh) | 1994-10-21 | 2004-04-28 | Nps药物有限公司 | 钙受体活性化合物 |
| JPH0915744A (ja) | 1995-06-29 | 1997-01-17 | Fuji Photo Film Co Ltd | 磁気ヘッドの検査方法及びフィルムキャリア |
| JP3522930B2 (ja) | 1995-12-06 | 2004-04-26 | 花王株式会社 | 抗菌剤及びこれを含有する口腔用組成物 |
| EP0881220A4 (en) | 1996-02-15 | 1999-04-21 | Mitsubishi Chem Corp | DIARYLSULTAME DERIVATIVES |
| KR19990087814A (ko) | 1996-04-24 | 1999-12-27 | 다케다 야쿠힌 고교 가부시키가이샤 | 과지방혈증 방지제로서의 융합 이미다조피리딘유도체 |
| US6218506B1 (en) | 1997-02-05 | 2001-04-17 | Northwestern University | Amyloid β protein (globular assembly and uses thereof) |
| US6518315B1 (en) | 1997-10-21 | 2003-02-11 | The University Of Sydney | Medicinal uses of phenylaikanols and derivatives |
| CO4980891A1 (es) | 1997-11-14 | 2000-11-27 | Sanofi Sa | Asociacion de principios activos para el tratamiento de la demencia senil de tipo azheimer |
| CO5011072A1 (es) | 1997-12-05 | 2001-02-28 | Lilly Co Eli | Etanolaminas pirazinil substituidas como agfonistas de los receptores |
| IL138686A0 (en) | 1999-10-01 | 2001-10-31 | Pfizer Prod Inc | α- SULFONYLAMINO HYDROXAMIC ACID INHIBITORS OF MATRIX METALLOPROTEINASES FOR THE TREATMENT OF PERIPHERAL OR CENTRAL NERVOUS SYSTEM DISORDERS |
| WO2001030335A2 (en) | 1999-10-22 | 2001-05-03 | The Board Of Trustees Of The University Of Illinois | Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease |
| DE10027151A1 (de) | 2000-05-31 | 2001-12-06 | Bayer Ag | Herbizide Mittel auf Basis von substituierten Carbonsäureamiden |
| DE60105023T2 (de) | 2000-06-28 | 2005-08-18 | Smithkline Beecham P.L.C., Brentford | Nassvermahlungsverfahren |
| EP1481061B1 (en) | 2001-03-05 | 2011-06-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Denaturant stable and/or protease resistant, chaperone-like oligomeric proteins, polynucleotides encoding same and their uses |
| JP4312402B2 (ja) | 2001-07-31 | 2009-08-12 | 有限会社大長企画 | 抗うつ剤、抗更年期障害剤、抗老人性痴呆症剤、抗アルツハイマー剤 |
| WO2003016274A2 (en) | 2001-08-21 | 2003-02-27 | Sepracor, Inc. | 2-substituted piperidines that are ligands for monoamine receptors and transporters |
| US6991814B2 (en) | 2001-12-13 | 2006-01-31 | Council Of Scientific And Industrial Research | Herbal medicaments for the treatment of neurocerebrovascular disorders |
| EP1453528B1 (en) | 2001-12-14 | 2009-07-22 | Council of Scientific and Industrial Research | Compositions containing curcuma extracts for the treatment of neurocerebrovascular disorders |
| JP2004002517A (ja) | 2002-05-31 | 2004-01-08 | Dae Sil Kim | 生姜成分を含む石鹸の組成物及びその製造方法 |
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| DE10320560A1 (de) | 2003-05-07 | 2004-01-29 | Brosig, Stefan, Dr. | Mittel zur Bekämpfung der Alzheimer Erkrankung und/oder der Parkinson Krankheit |
| US7829562B2 (en) | 2003-06-12 | 2010-11-09 | M's Science Corporation | Sigma ligands for neuronal regeneration and functional recovery |
| WO2004110387A2 (en) | 2003-06-12 | 2004-12-23 | Agy Therapeutics, Inc. | Sigma ligands for neuronal regeneration and functional recovery |
| HRP20060326A2 (hr) | 2004-03-12 | 2007-02-28 | Egis Gy�gyszergy�r Nyrt. | Kombinirani farmaceutski kompozit za inhibiciju pada kognitivnih funkcija |
| WO2005115366A1 (ja) | 2004-05-31 | 2005-12-08 | Kaneka Corporation | ウコン精油成分を含有する生活習慣病予防・改善剤 |
| AU2005253776B8 (en) | 2004-06-21 | 2012-02-02 | King's College London | Screening methods using c-Abl, Fyn and Syk in combination with tau protein |
| TW200613272A (en) | 2004-08-13 | 2006-05-01 | Astrazeneca Ab | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators |
| JP2008512417A (ja) | 2004-09-10 | 2008-04-24 | ユセベ ファルマ ソシエテ アノニム | シグマ受容体リガンド |
| WO2006047254A1 (en) | 2004-10-22 | 2006-05-04 | Regents Of The University Of Minnesota | Assemblies of oligomeric amyloid beta protein and uses thereof |
| WO2006066118A2 (en) | 2004-12-15 | 2006-06-22 | Neuralab Limited | Contextual fear test for predicting efficacy of alzheimer immunotherapeutic treatment |
| ATE458754T1 (de) | 2005-03-05 | 2010-03-15 | Abbott Gmbh & Co Kg | Screening-verfahren, verfahren zur aufreinigung nichtdiffundierbarer a-beta-oligomere, selektive antikörper gegen diese nichtdiffundierbaren a- beta-oligomere und verfahren zur herstellung dieser antikörper |
| WO2006138349A1 (en) | 2005-06-15 | 2006-12-28 | Kim Darrick S H L | Synergistic pharmaceutical compositions useful in prevention and treatment of beta-amyloid protein-induced disease including sage and rosemary derived compounds |
| TW200726774A (en) | 2005-06-30 | 2007-07-16 | Merck & Co Inc | Composition and method for producing stable amyloid beta oligomers |
| US20070021413A1 (en) | 2005-07-20 | 2007-01-25 | Peter Herold | Diamino alcohols as therapeutic compounds |
| ITRM20060007A1 (it) | 2006-01-05 | 2007-07-06 | Univ Bari | Recettore sigma-2 metodo di screening di ligandi specifici e uso degli stessi in metodi diagnostici o terapeutici |
| US20070218491A1 (en) | 2006-02-08 | 2007-09-20 | Oligomerix, Inc. | Oligomerization of amyloid proteins |
| MX2008011754A (es) | 2006-03-17 | 2008-09-30 | Herbalscience Singapore Pte Ltd | Extractos y metodos que comprenden especies de curcuma. |
| WO2007112288A2 (en) | 2006-03-23 | 2007-10-04 | Mount Sinai School Of Medicine | Cardiovascular composition and use the same for the treatment of alzheimers disease |
| WO2007126473A2 (en) | 2006-04-10 | 2007-11-08 | Oligomerix, Inc. | Oligomerization of amyloid proteins |
| US8357781B2 (en) | 2006-06-01 | 2013-01-22 | Janssen Alzheimer Immunotherapy | Neuroactive fragments of APP |
| US7561775B2 (en) | 2006-08-22 | 2009-07-14 | Senko Advanced Components, Inc. | Fiber optic protective shutter |
| CA2662723A1 (en) | 2006-09-08 | 2008-03-13 | Vib Vzw | Means and methods for the production of amyloid oligomers |
| WO2008042755A2 (en) | 2006-09-29 | 2008-04-10 | Cognition Therapeutics, Inc. | Inhibitors of cognitive decline |
| US20080131233A1 (en) | 2006-10-17 | 2008-06-05 | Yao Chun I | Plate-shaped fastener device |
| US20100028333A1 (en) | 2006-12-15 | 2010-02-04 | Getty Krista L | Receptor for amyloid beta and uses thereof |
| US20080171757A1 (en) | 2007-01-11 | 2008-07-17 | Government Of The Us, As Represented By The Secretary, Department Of Health And Human Serivces | Methods to identify inhibitors of cell sickling |
| US9217036B2 (en) | 2007-04-26 | 2015-12-22 | Yale University | Prion protein as a receptor for amyloid-β oligomers |
| CN101808647A (zh) | 2007-05-15 | 2010-08-18 | 海利空医疗公司 | 通过抑制Gpr12治疗认知障碍的方法 |
| CN101121670A (zh) | 2007-09-11 | 2008-02-13 | 上海紫源制药有限公司 | 一种3,4-二甲氧基-N-[3-(4-甲氧基苯基)-1-甲基-正丙基]-β-苯乙胺盐酸盐的制备方法 |
| WO2009048631A1 (en) | 2007-10-11 | 2009-04-16 | University Of Tennessee Research Foundation | PREPARATION OF PURIFIED COVALENTYLY CROSS-LINKED A β OLIGOMERS AND USES THEREOF |
| US8304547B2 (en) | 2007-10-24 | 2012-11-06 | Astellas Pharma Inc. | Azolecarboxamide compound or salt thereof |
| WO2009059214A1 (en) | 2007-11-02 | 2009-05-07 | The Regents Of The University Of California | Abeta-binding small molecules |
| WO2009067493A2 (en) | 2007-11-19 | 2009-05-28 | Envivo Pharmaceuticals, Inc. | 1,3,5 tri-subtituted benzenes for treatment of alzheimer's disease and other disorders |
| CN102203124A (zh) | 2008-07-25 | 2011-09-28 | 雅培制药有限公司 | 淀粉状蛋白β肽类似物，其寡聚物，用于制备的方法以及包括所述类似物或寡聚物的组合物，及其用途 |
| WO2010062260A1 (en) | 2008-11-29 | 2010-06-03 | The Thailand Research Fund | Virus and target cell interaction inhibition |
| WO2010088450A2 (en) | 2009-01-30 | 2010-08-05 | Celladon Corporation | Methods for treating diseases associated with the modulation of serca |
| DK2408905T3 (en) | 2009-03-16 | 2017-08-28 | Pangu Biopharma Ltd | Compositions and Methods comprising Histidyl-tRNA Synthetase Splicing Variants with Non-Canonical Biological Activities |
| US7972164B2 (en) | 2009-03-24 | 2011-07-05 | Tyco Electronics Corporation | Connector assembly with a latch |
| CN105968022A (zh) * | 2009-04-09 | 2016-09-28 | 考格尼申治疗股份有限公司 | 认知衰退的抑制剂 |
| US9493834B2 (en) | 2009-07-29 | 2016-11-15 | Pharnext | Method for detecting a panel of biomarkers |
| BR112012002246A2 (pt) * | 2009-07-31 | 2019-09-24 | Cognition Therapeutics Inc | composto, composto ou sal farmaceutico aceitavel deste, composição farmaceutica, metodo para inibir, tratar e/ou reduzir o declinio cognitivol e/ou doença de akzhmer em um paciente |
| US20150160228A1 (en) | 2010-02-05 | 2015-06-11 | Susan Catalano | Compositions and method for determining the efficacy of amyloidosis treatments |
| US20130071330A1 (en) | 2010-02-26 | 2013-03-21 | Susan Catalano | Methods of identifying agents effective to treat cognitive decline and diseases associated therewith |
| WO2012027548A1 (en) | 2010-08-25 | 2012-03-01 | The Feinstein Institute For Medical Research | Compounds and methods for prevention and treatment of alzheimer's and other diseases |
| SG192596A1 (en) | 2011-02-02 | 2013-09-30 | Cognition Therapeutics Inc | Isolated compounds from turmeric oil and methods of use |
| US20170049723A1 (en) | 2011-02-02 | 2017-02-23 | Cognition Therapeutics, Inc. | Isolated compounds from turmeric oil and methods of use |
| AU2012298617B2 (en) | 2011-08-25 | 2016-07-14 | Cognition Therapeutics, Inc. | Compositions and methods for treating neurodegenerative disease |
| CA2846604A1 (en) | 2011-08-25 | 2013-02-28 | Cognition Therapeutics, Inc. | Compositions and methods for treating neurodegenerative disease |
| AT511906B1 (de) | 2011-08-30 | 2016-05-15 | Blum Gmbh Julius | Schublade |
| WO2015020523A1 (en) | 2013-08-07 | 2015-02-12 | Stichting Vu-Vumc | Biomarkers for early diagnosis of alzheimer's disease |
| DK3099296T3 (en) * | 2014-01-31 | 2019-04-15 | Cognition Therapeutics Inc | ISO-INDOLINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE |
| IL270251B2 (en) | 2017-05-15 | 2025-01-01 | Cognition Therapeutics Inc | 1-Phenyl-1,1-dimethyl-2-(piperidinyl/pyrrolidinyl/piperazinyl)ethane derivatives and pharmaceutical preparations containing them |
| EP3704092A4 (en) * | 2017-11-01 | 2021-08-25 | Cognition Therapeutics, Inc. | ISOINDOLINE COMPOSITIONS AND METHODS OF TREATMENT OF NEURODEGENERATIVE DISEASE |
| CN110283082A (zh) | 2019-07-15 | 2019-09-27 | 泰州职业技术学院 | 一种3-苯基丙胺的制备方法 |
| EP4103604A4 (en) * | 2020-02-13 | 2024-03-27 | Cognition Therapeutics, Inc. | Method of decreasing amyloid beta monomer levels in patients with cognitive decline |
| EP4259129A4 (en) | 2020-12-11 | 2024-11-27 | Cognition Therapeutics, Inc. | COMPOSITIONS FOR THE TREATMENT OF DRY AGE-RELATED MACULAR DEGENERATION (AMD) |
-
2015
- 2015-01-30 DK DK15743281.6T patent/DK3099296T3/en active
- 2015-01-30 WO PCT/US2015/013754 patent/WO2015116923A1/en not_active Ceased
- 2015-01-30 CN CN201580017497.0A patent/CN106163516B/zh active Active
- 2015-01-30 NZ NZ722599A patent/NZ722599A/en unknown
- 2015-01-30 CA CA2938212A patent/CA2938212C/en active Active
- 2015-01-30 US US15/115,187 patent/US9796672B2/en active Active
- 2015-01-30 AU AU2015210852A patent/AU2015210852B2/en active Active
- 2015-01-30 EP EP19154222.4A patent/EP3498692B1/en active Active
- 2015-01-30 RU RU2016134677A patent/RU2692258C2/ru active
- 2015-01-30 MX MX2016009845A patent/MX368755B/es active IP Right Grant
- 2015-01-30 DK DK19154222.4T patent/DK3498692T3/da active
- 2015-01-30 JP JP2016549224A patent/JP6517827B2/ja active Active
- 2015-01-30 EP EP15743281.6A patent/EP3099296B1/en active Active
- 2015-01-30 EP EP22155541.0A patent/EP4023294A1/en active Pending
- 2015-01-30 ES ES15743281T patent/ES2721001T3/es active Active
- 2015-01-30 BR BR112016017808-4A patent/BR112016017808B1/pt active IP Right Grant
- 2015-01-30 KR KR1020167023951A patent/KR102331422B1/ko active Active
- 2015-01-30 ES ES19154222T patent/ES2915833T3/es active Active
-
2016
- 2016-07-28 IL IL247003A patent/IL247003B/en active IP Right Grant
-
2017
- 2017-09-11 US US15/700,923 patent/US10207991B2/en active Active
-
2018
- 2018-12-21 US US16/230,238 patent/US10611728B2/en active Active
-
2020
- 2020-02-06 US US16/783,943 patent/US11691947B2/en active Active
-
2023
- 2023-04-27 US US18/308,037 patent/US12466795B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2721001T3 (es) | Derivado de isoindolina, y composiciones y métodos para tratar una enfermedad neurodegenerativa | |
| DOP2020000102A (es) | Compuestos útiles para inhibir a cdk7 | |
| EA201691582A1 (ru) | Новые фармацевтические препараты | |
| PH12016502179A1 (en) | Inhibitors of lysine specific demethylase-1 | |
| MX388170B (es) | Polimorfos de selinexor | |
| EA201791420A1 (ru) | Соединения триазолопиримидина и их применения | |
| MX2017015211A (es) | Compuestos de naftiridina como inhibidores de quinasa jak. | |
| CR20160564A (es) | Dinucleótidos cíclicos como moduladores de sting | |
| EA201692203A1 (ru) | Соединения, ингибирующие tank-связывающую киназу | |
| PE20151654A1 (es) | Inhibidores de cdc7 | |
| EA201691940A1 (ru) | Новые соединения | |
| CL2016001458A1 (es) | Derivado de sulfonamida o sales de adición de ácido farmaceuticamente aceptables del mismo. | |
| DOP2015000201A (es) | Compuestos de azabencimidazol como inhibidores de pde4 isoenzimas para el tratamiento del snc y otros trastornos | |
| TN2015000519A1 (en) | Small molecule inhibitors of fibrosis | |
| EA201691481A1 (ru) | ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ | |
| MX2021005052A (es) | Oxiesteroles y métodos de uso de los mismos. | |
| EA202090098A1 (ru) | Фармацевтические композиции терапевтически активных соединений | |
| CL2016002940A1 (es) | Derivado de carotenoides, sal farmacéuticamente aceptable del mismo, o éster o amida farmacéuticamente aceptables del mismo | |
| CY1122264T1 (el) | Ppar ενωσεις για χρηση στην αντιμετωπιση των ινωτικων νοσων | |
| SV2017005381A (es) | Compuestos de imidazopiridazina | |
| MX2019013194A (es) | Procedimientos para preparar compuestos de tipo oxatiazina. | |
| PH12017500459A1 (en) | Azetidinyloxyphenylpyrrolidine compounds | |
| MX2020003732A (es) | Derivado de anillo fusionado como inhibidor del receptor a2a. | |
| AR105821A1 (es) | COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T | |
| EA201791945A1 (ru) | Пирролидинкарбоксамидопроизводные и способы их получения и их применение |